



# **VENUS REMEDIES LIMITED**

## **Media Coverage Report**

**Press Release: Venus Remedies Secures Exclusive In-Licensing Rights from Infex Therapeutics to Develop and Commercialize**

**Date: 25 - 28 February 2025**



**Adfactors Public Relations**  
Knowledge-driven communications

## Table of Contents:

VENUS REMEDIES LTD				
Print				
S. No	Date	Publication	Headline	Edition/Page/News Link
1	26.02.2025	Business Standard	Venus Remedies to develop AMR with UK firm	Mumbai_Chandigarh_Page 07
2	26.02.2025	Business Standard (Hindi)	एंटीबायोटिक प्रतिरोध का तोड़ तैयार करेगी वीनस	Mumbai_Page 10
3	26.02.2025	The Tribune	Venus Remedies inks pact with UK Firm	Delhi_Chandigarh_Page 12
Online				
4	27.02.2025	The Economic Times (Pharma)	Venus looks to tackle Meropenem resistance with Infex under trial candidate	<a href="https://pharma.economictimes.indiatimes.com/news/pharma-industry/venus-looks-to-tackle-meropenem-resistance-with-infex-under-trial-candidate/118606226">https://pharma.economictimes.indiatimes.com/news/pharma-industry/venus-looks-to-tackle-meropenem-resistance-with-infex-under-trial-candidate/118606226</a>
5	25.02.2025	Business Standard	Venus Remedies to co-develop antibiotic resistance blocker with UK firm	<a href="https://www.business-standard.com/companies/news/venus-remedies-to-co-develop-antibiotic-resistance-blocker-with-uk-firm-125022500532_1.html">https://www.business-standard.com/companies/news/venus-remedies-to-co-develop-antibiotic-resistance-blocker-with-uk-firm-125022500532_1.html</a>
6	25.02.2025	Business Standard (Hindi)	एंटीबायोटिक प्रतिरोध का तोड़ तैयार करेगी Venus Remedies, नई रिसर्च की खबर के बाद चढ़ा कंपनी का शेयर	<a href="https://hindi.business-standard.com/companies/venus-remedies-will-prepare-to-raise-companys-share-after-new-research-in-india-416906">https://hindi.business-standard.com/companies/venus-remedies-will-prepare-to-raise-companys-share-after-new-research-in-india-416906</a>
7	26.02.2025	The Tribune	India, EU to renew FTA negotiations	<a href="https://www.tribuneindia.com/news/business/india-eu-to-renew-fta-negotiations/">https://www.tribuneindia.com/news/business/india-eu-to-renew-fta-negotiations/</a>
8	25.02.2025	Outlook Business	Venus Remedies Inks Licensing Pact with UK Entity to Develop MET-X in India	<a href="https://www.outlookbusiness.com/corporate/venus-remedies-inks-licensing-pact-with-uk-entity-to-develop-met-x-in-india/">https://www.outlookbusiness.com/corporate/venus-remedies-inks-licensing-pact-with-uk-entity-to-develop-met-x-in-india/</a>
9	25.02.2025	The Week	Venus Remedies inks licensing pact with UK entity to develop MET-X in India	<a href="https://www.theweek.in/wire-updates/business/2025/02/25/dcm16-biz-venus-remedies-met-x.html">https://www.theweek.in/wire-updates/business/2025/02/25/dcm16-biz-venus-remedies-met-x.html</a>
10	25.02.2025	Express Pharma	Venus Remedies partners with Infex Therapeutics for clinical development of MET-X in India	<a href="https://www.expresspharma.in/venus-remedies-partners-with-infex-therapeutics-for-clinical-development-of-met-x-in-india/">https://www.expresspharma.in/venus-remedies-partners-with-infex-therapeutics-for-clinical-development-of-met-x-in-india/</a>
11	25.02.2025	Biospectrum India	Venus Remedies partners with	<a href="https://www.biospectrumindia.com/ne">https://www.biospectrumindia.com/ne</a>

			UK-based Infex Therapeutics to develop anti-bacterial MET-X in India	<a href="https://www.medgatetoday.com/venus-remedies-partners-with-uk-based-infex-therapeutics-to-develop-anti-bacterial-met-x-in-india.html">ws/16/25729/venus-remedies-partners-with-uk-based-infex-therapeutics-to-develop-anti-bacterial-met-x-in-india.html</a>
12	27.02.2025	Medgate Today	Venus Remedies Secures Exclusive In-Licensing Rights from Infex Therapeutics to Develop and Commercialize MET-X in India	<a href="https://medgatetoday.com/venus-remedies-secures-exclusive-in-licensing-rights-from-infex-therapeutics-to-develop-and-commercialize-met-x-in-india/">https://medgatetoday.com/venus-remedies-secures-exclusive-in-licensing-rights-from-infex-therapeutics-to-develop-and-commercialize-met-x-in-india/</a>
13	25.02.2025	Pharma Biz	Venus Remedies enters exclusive licensing agreement with Infex Therapeutics to develop and commercialize MET-X in India	<a href="https://www.pharmabiz.com/NewsDetails.aspx?aid=175496&amp;sid=2">https://www.pharmabiz.com/NewsDetails.aspx?aid=175496&amp;sid=2</a>
14	25.02.2025	Medicircle	Venus Remedies Secures Exclusive In-Licensing Rights from Infex Therapeutics to Develop and Commercialize MET-X in India	<a href="https://medicircle.in/venus-remedies-secures-exclusive-in-licensing-rights-from-infex-therapeutics-to-develop-and-commercialize-metx-in-india">https://medicircle.in/venus-remedies-secures-exclusive-in-licensing-rights-from-infex-therapeutics-to-develop-and-commercialize-metx-in-india</a>
15	27.02.2025	Indian Pharma Post	Venus Remedies secures in-licensing rights from Infex Therapeutics to develop and commercialize MET-X in India	<a href="https://www.indianpharmapost.com/news/venus-remedies-secures-in-licensing-rights-from-infex-therapeutics-to-develop-and-commercialize-met-x-in-india-16834">https://www.indianpharmapost.com/news/venus-remedies-secures-in-licensing-rights-from-infex-therapeutics-to-develop-and-commercialize-met-x-in-india-16834</a>
16	27.02.2025	India Med Today	Venus Remedies to develop and commercialise MET-X in India	<a href="https://indiamedtoday.com/venus-remedies-to-develop-and-commercialise-met-x-in-india/">https://indiamedtoday.com/venus-remedies-to-develop-and-commercialise-met-x-in-india/</a>
17	27.02.2025	The Indian Practitioner	Venus Remedies and Infex Therapeutics Partners to Develop MET-X	<a href="https://theindianpractitioner.com/venus-remedies-and-infex-therapeutics-unite-to-develop-met-x/">https://theindianpractitioner.com/venus-remedies-and-infex-therapeutics-unite-to-develop-met-x/</a>
18	26.02.2025	Clival	Venus Remedies Partners with Infex for MET-X Drug Development	<a href="https://clival.com/news/venus-remedies-partners-with-infex-for-met-x-development-in-india">https://clival.com/news/venus-remedies-partners-with-infex-for-met-x-development-in-india</a>
19	25.02.2025	Devdiscourse	Venus Remedies Partners with Infex Therapeutics for Innovative Inhibitor	<a href="https://www.devdiscourse.com/article/health/3276626-venus-remedies-partners-with-infex-therapeutics-for-innovative-inhibitor">https://www.devdiscourse.com/article/health/3276626-venus-remedies-partners-with-infex-therapeutics-for-innovative-inhibitor</a>
20	25.02.2025	Daily Excelsior	Venus Remedies inks licensing pact with UK entity to develop MET-X in India	<a href="https://www.dailyexcelsior.com/venus-remedies-inks-licensing-pact-with-uk-entity-to-develop-met-x-in-india/">https://www.dailyexcelsior.com/venus-remedies-inks-licensing-pact-with-uk-entity-to-develop-met-x-in-india/</a>
21	25.02.2025	SME Street	Venus Remedies Partners with Infex for MET-X Drug Development	<a href="https://smestreet.in/sectors/venus-remedies-partners-with-infex-for-met-x-drug-development-8755205">https://smestreet.in/sectors/venus-remedies-partners-with-infex-for-met-x-drug-development-8755205</a>
22	25.02.2025	The Bengaluru Live	Venus Remedies Partners with Infex Therapeutics for Innovative Inhibitor	<a href="https://thebengalurlive.com/venus-remedies-partners-with-infex-therapeutics-for-innovative-inhibitor/">https://thebengalurlive.com/venus-remedies-partners-with-infex-therapeutics-for-innovative-inhibitor/</a>

23	25.02.2025	Business Upturn	Venus Remedies secures exclusive rights for MET-X clinical development in India	<a href="https://www.businessupturn.com/business/corporates/venus-remedies-secures-exclusive-rights-for-met-x-clinical-development-in-india/">https://www.businessupturn.com/business/corporates/venus-remedies-secures-exclusive-rights-for-met-x-clinical-development-in-india/</a>
24	25.02.2025	Business News This Week	Venus Remedies Secures Exclusive In-Licensing Rights for MET-X from Infex Therapeutics in India	<a href="https://businessnewsthisweek.com/news/venus-remedies-secures-exclusive-in-licensing-rights-for-met-x-from-infex-therapeutics-in-india/">https://businessnewsthisweek.com/news/venus-remedies-secures-exclusive-in-licensing-rights-for-met-x-from-infex-therapeutics-in-india/</a>
25	25.02.2025	Business Micro	Venus Remedies Partners with Infex Therapeutics to Develop and Commercialize MET-X in India	<a href="https://businessmicro.in/news/venus-remedies-partners-with-infex-therapeutics-to-develop-and-commercialize-met-x-in-india/">https://businessmicro.in/news/venus-remedies-partners-with-infex-therapeutics-to-develop-and-commercialize-met-x-in-india/</a>
26	25.02.2025	News Patrolling	Venus Remedies Secures Exclusive In-Licensing Rights from Infex Therapeutics to Develop and Commercialize MET-X in India	<a href="https://newspatrolling.com/venus-remedies-secures-exclusive-in-licensing-rights-from-infex-therapeutics-to-develop-and-commercialize-met-x-in-india/">https://newspatrolling.com/venus-remedies-secures-exclusive-in-licensing-rights-from-infex-therapeutics-to-develop-and-commercialize-met-x-in-india/</a>
27	25.02.2025	Indian Web2	Venus Remedies Secures Exclusive In-Licensing Rights to Develop and Commercialize MET-X in India	<a href="https://www.indianweb2.com/2025/02/venus-remedies-secures-exclusive-in.html#google_vignette">https://www.indianweb2.com/2025/02/venus-remedies-secures-exclusive-in.html#google_vignette</a>
28	25.02.2025	Rediff Money	Venus Remedies Partners with UK Firm to Develop MET-X for Drug-Resistant Infections	<a href="https://money.rediff.com/news/market/venus-remedies-partners-with-uk-firm-to-develop-met-x-for-drug-resistant-infections/22667420250225">https://money.rediff.com/news/market/venus-remedies-partners-with-uk-firm-to-develop-met-x-for-drug-resistant-infections/22667420250225</a>

Date: 26 Feb 2025	Portal: Business Standard
Supplement – Print	Edition, Page No. - Mumbai & Chandigarh, 08

## Venus Remedies to develop AMR blocker with UK firm

SOHINI DAS  
Mumbai, 25 February

Venus Remedies is working with UK-based Infex Therapeutics for the clinical development of a drug that helps reduce resistance to beta lactam antibiotics like Meropenem.

Antimicrobial resistance (AMR) is a burning problem in India and the world, and MBL inhibitors are drugs that prevent bacterial enzymes MBLs from inactivating beta-lactam antibiotics. MBLs are a threat to public health because they make many antibiotics ineffective. No approved MBL inhibitors currently exist in the country and this is an unmet medical need at the moment.

AMR occurs when bacteria, viruses, fungi, and parasites no longer respond to antimicrobial medicines.

The drug, MET-X (metallo-beta-lactamase (MBL) inhibitor), is Infex Therapeutics' broad spectrum MBL-inhibitor, targeting Gram-negative bacteria. These pathogens produce MBL enzymes to deactivate beta-lactam antibiotics, such as meropenem, and evade antibiotic clearance of disease.

MET-X blocks MBL resistance, restoring antibiotic activity. Venus Remedies will spearhead the clinical development of the drug, registration, as well as commercialisation in India. The firm's

### VITAL SIGNS

- Clinical trials to start next year, and drug can be in market by 2031-32
- No approved MBL inhibitor exists in India at present
- Meropenem is one of the widely prescribed antibiotics in India



stock ended day's trade on BSE up 1.34 per cent.

The initial development phase will focus on integrating MET-X with meropenem to tackle drug-resistant Gram-negative bacteria, with Venus Remedies holding exclusive marketing rights within India.

In India, meropenem resistance is reported to be as high as 62-87 per cent in WHO critical priority pathogens like *K. pneumoniae* and *A. baumannii*, according to the Indian Council for Medical Research (ICMR) Antimicrobial Resistance Research and Surveillance Network Annual report 2023, with as high as 50 per cent being directly attributable to MBL prevalence.

Saransh Chaudhary, president, Global Critical Care, Venus Remedies, and CEO, Venus Medicine Research Centre told *Business Standard* that there are roughly around 250,000 deaths that happen due to carbapenem resistance globally. Meropenem is a subset and the most widely used car-

bapenem. So, one can estimate that roughly 20 per cent of these deaths happen in India.

"But the true number is probably going to be a little bit higher because in India, the meropenem is one of the most widely used and is actually amongst the top 10 most described drugs in the country," he added. He pointed out that India is now at the epicentre of superbugs because of the very high usage of antibiotics and prescription lapses.

Two million deaths are projected to occur in India due to AMR by 2050. Globally, this number can touch 10 million.

Under the terms of the agreement, Venus Remedies will commence with a phase-I trial involving healthy volunteers in India, evaluating MET-X in combination with meropenem. Following successful phase-I outcomes, the focus will shift to Phase II/III trials targeting drug-resistant complicated Urinary Tract infections (cUTIs), prevalent in hospital settings.

The India trials will adhere to international standards, the company claimed, adding that these would be compliant with regulations from the FDA, EMA, and MHRA, which will also support further development and global commercialisation efforts for MET-X.

Chaudhary said that they plan to initiate phase-I trials next year. The study would take about a year to complete.

"Hence, we are also hoping that we can do a combined pivotal study given that the combination is going to address a major unmet medical need. And that trial is going to start sometime in FY28 and will likely take about two to three years to complete depending on the sample size and the recruitment that we do. We should be in a position to launch the product or file for regulatory approvals around 2030 with the market entry anticipated anywhere around 31-32," he explained.

Peter Jackson, CEO of Infex Therapeutics, said, "By leveraging Venus Remedies' robust expertise in critical care antibiotics, we can accelerate MET-X as our second clinical-stage drug programme. Crucially, the international standards of these trials will also support future regulatory filings in the UK, US, Europe, and other global markets."

More on [business-standard.com](https://www.business-standard.com)

# एंटीबायोटिक प्रतिरोध का तोड़ तैयार करेगी वीनस

सोहिनी दास  
मुंबई, 25 फरवरी

वीनस रेमेडीज ब्रिटेन की इन्फेक्स थेराप्यूटिक्स के साथ मिलकर मेट-एक्स दवा या मेटलो-बीटा-लैक्टम (एमबीएल) अवरोधक तैयार कर रही है। यह मेरोपेनम जैसी बीटा लैक्टम एंटीबायोटिक दवाओं को बेअसर करने वाला प्रभाव कम करने में मदद करती है।

रोगाणुनाशी दवाओं का प्रतिरोध (एमआर) भारत सहित दुनिया भर में गंभीर समस्या बन गया है। एमबीएल इनहिबिटर ऐसी दवा है जो बीटा-लैक्टम एंटीबायोटिक दवाओं को बेअसर करने वाले जीवाणु एंजाइम एमबीएल को रोकती है। एमबीएल जन स्वास्थ्य के लिए खतरा है क्योंकि वह कई एंटीबायोटिक दवाओं का असर खत्म कर देता है। देश में अभी कोई स्वीकृत एमबीएल इनहिबिटर नहीं है और चिकित्सा के क्षेत्र में इसकी बहुत जरूरत है। एमआर वह स्थिति होती है, जब जीवाणु, विषाणु, फफूंद और परजीवी पर रोगाणुनाशी दवाओं का असर बंद हो जाता है।

नई दवा विकसित करने की खबर से वीनस रेमेडीज का शेयर चढ़ गया। बंबई स्टॉक एक्सचेंज पर आज यह शेयर 1.34 फीसदी चढ़कर 310.55 रुपये पर बंद हुआ।

मेट-एक्स इन्फेक्स थेराप्यूटिक्स का प्रमुख एमबीएल-इनहिबिटर है, जो ग्राम-नेगेटिव बैक्टीरिया को निशाना बनाता है। ये रोगाणु एमबीएल एंजाइम बनाते हैं, जो मेरोपेनम जैसे बीटा-लैक्टम एंटीबायोटिक को निष्क्रिय बना देता है। मेट-एक्स इस स्थिति से लड़ता है और एंटीबायोटिक को सक्रिय बनाता है। वीनस रेमेडीज भारत में मेट-एक्स दवा

का क्लिनिकल विकास, पंजीकरण तथा मार्केटिंग करेगी। शुरुआती दौर में दवा प्रतिरोधी ग्राम-नेगेटिव बैक्टीरिया से निपटने के लिए मेट-एक्स को मेरोपेनम के साथ मिलाने पर ध्यान दिया जाएगा और भारत में इसे बेचने का अधिकार केवल वीनस रेमेडीज के पास होगा। भारतीय आयुर्विज्ञान अनुसंधान परिषद (आईसीएमआर) की एंटीमाइक्रोबियल रजिस्ट्रेशन रिसर्च एंड सर्विलांस नेटवर्क वार्षिक रिपोर्ट 2023 के अनुसार विश्व स्वास्थ्य संगठन (डब्ल्यूएचओ) के अत्यधिक प्राथमिकता वाले रोगाणुओं में मेरोपेनम का प्रतिरोध 62 से 87 फीसदी तक है, जिसमें से 50 फीसदी सीधे एमबीएल के कारण है। केन्यानी और एबोमनई ऐसे ही रोगाणु हैं।

वीनस रेमेडीज में ग्लोबल क्रिटिकल केयर के प्रेसिडेंट और वीनस मेडिकल रिसर्च सेंटर के सीईओ सारांश चौधरी ने विज्ञान स्टैंडर्ड को बताया कि दुनिया भर में काबापेनम दवा के प्रतिरोध के कारण लगभग 2.50 लाख मौतें होती हैं। मेरोपेनम उसी काबापेनम का सबसेट है और भारत में सबसे ज्यादा इस्तेमाल होता है। इसलिए मान सकते हैं कि इनमें से करीब 20 फीसदी मौतें भारत में होती हैं। उन्होंने कहा, 'सही आंकड़ा शायद कुछ ज्यादा होगा क्योंकि भारत में मेरोपेनम सबसे ज्यादा इस्तेमाल होने वाली दवाओं में है और डॉक्टरों के पर्चों में सबसे ज्यादा लिखी जाने वाली 10 दवाओं में शामिल है।'

अनुमान है कि 2050 तक भारत में ही एमआर के कारण 20 लाख मौतें होंगी और दुनिया भर में मौतों का आंकड़ा 1 करोड़ तक पहुंच सकता है।

(शेष पृष्ठ 2 पर)

## ... तोड़ तैयार करेगी वीनस रेमेडीज

पृष्ठ 1 का शेष



### नई दवा बनाएगी कंपनी

■ ब्रिटेन की कंपनी इन्फेक्स थेरेप्यूटिक्स के साथ मिलकर बनाएगी मेट-एक्स दवा

■ भारत में अभी एक भी स्वीकृत एमबीएल अवरोधक मौजूद नहीं है

■ एंटीबायोटिक को बेअसर करने वाले प्रतिरोधकों के कारण दुनिया भर में लाखों मौतें हो रही हैं

■ अगले साल शुरू होगा क्लिनिकल परीक्षण, 2031-32 तक बाजार में दवा आने की उम्मीद

समझौते की शर्तों के मुताबिक वीनस रेमेडीज भारत में स्वस्थ बाल्टेरियो पर पहले चरण का परीक्षण करेगी, जिसमें मेरोपेनम के साथ मेट-एक्स को मिलाकर देखा जाएगा। पहले चरण के नतीजे सफल होने पर दूसरे और तीसरे चरण का परीक्षण किया जाएगा, जिसमें अस्पताल भी शामिल होंगे। इसमें दवा प्रतिरोध के कारण मृत नलिका में होने वाले गंभीर संक्रमण पर यह दवा आजमाई जाएगी। कंपनी ने दवा किया कि भारत में परीक्षण के दौरान अंतरराष्ट्रीय मानकों का पालन किया जाएगा और सब कुछ एफडीए, ईएमए और एमएचआरए के नियमों के अनुरूप होगा। इससे मेट-एक्स के लिए आगे के विकास और वैश्विक मार्केटिंग में भी मदद मिलेगी। चौधरी ने कहा कि वे अगले साल पहले चरण का परीक्षण शुरू करने की योजना बना रहे हैं, जिसे पूरा होने में करीब एक साल लग जाएगा। उन्होंने कहा, 'हम 2030 के आसपास उत्पाद पेश कर पाएंगे या नियामक से मंजूरी की अर्जी डाल पाएंगे। दवा 2031-32 तक बाजार में आ सकती है।'

इन्फेक्स थेराप्यूटिक्स के सीईओ पीटर जैक्सन ने कहा, 'एंटीबायोटिक दवाओं में वीनस रेमेडीज की महारत का फायदा उठाकर हम मेट-एक्स को अपने दूसरे क्लिनिकल-स्टेज ड्रग प्रोग्राम के तौर पर बढ़ा सकते हैं। ये परीक्षण अंतरराष्ट्रीय मानक के होंगे, जिससे ब्रिटेन, अमेरिका, यूरोप और दूसरे बाजारों में नियामकीय मंजूरी पाना आसान होगा। क्लिनिकल परीक्षण से पहले के अध्ययनों में मेट-एक्स काफी असरदार रहा है और यह ग्राम-नेगेटिव एमबीएल-प्रतिरोधी संक्रमण से पीड़ित रोगियों के उपचार में कारगर हो सकता है।' वीनस रेमेडीज के चेयरमैन और प्रबंध निदेशक पवन चौधरी ने कहा, 'मेट-एक्स का लाइसेंस दवा प्रतिरोधी संक्रमण के लिए क्रांतिकारी समाधान प्रदान करने की दिशा में बड़ा कदम है। हमारा उद्देश्य एमबीएल-उत्पादक रोगाणुओं के खिलाफ प्रभावी समाधान विकसित करना, स्वास्थ्य सेवा आवश्यकताओं को पूरा करना और क्रिटिकल केयर में परिवर्तनकारी उपचार तथा नवाचार देते रहना है।'

Date: 26 Feb 2025	Portal: The Tribune
Supplement – Print	Edition, Page No. - Delhi & Chandigarh, 12

## IN BRIEF

### India, EU to renew FTA negotiations

**NEW DELHI:** India and the European Union will this week take stock of their negotiations for an ambitious free trade deal and broadly firm up a new strategic agenda. [PTI](#)

### Venus Remedies inks pact with UK firm

**NEW DELHI:** Venus Remedies said it has joined hands with UK-based Infex Therapeutics for the development of METX, an inhibitor, to tackle infections caused by drug-resistant gram-negative bacteria. [PTI](#)

# Online

Date: 27 Feb 2025	Portal: The Economic Times
Supplement – Digital	Link: <a href="https://pharma.economictimes.indiatimes.com/news/pharma-industry/venus-looks-to-tackle-meropenem-resistance-with-infex-under-trial-candidate/118606226">https://pharma.economictimes.indiatimes.com/news/pharma-industry/venus-looks-to-tackle-meropenem-resistance-with-infex-under-trial-candidate/118606226</a>

## ET Pharma

### Venus looks to tackle Meropenem resistance with Infex under trial candidate

As patients are increasingly reflecting resistance against meropenem, one of its marketers, Venus Remedies, has acquired India commercial rights of an under-trial candidate from UK-based Infex Therapeutics and is going to test the two drug integration over drug-resistant Gram-negative bacteria.



Online Bureau • ET Pharma  
Updated On Feb 27, 2025 at 06:45 PM IST



New Delhi: In a bid to tackle the Meropenem resistance, a drug marketed by Venus Remedies, the Indian drugmaker has acquired the commercial rights of an under-trial MBL inhibitor developed by a UK-based

anti-infectives specialist Infex Therapeutics.

Date: 25 Feb 2025	Portal: Business Standard
Supplement – Digital	Link: <a href="https://www.business-standard.com/companies/news/venus-remedies-to-co-develop-antibiotic-resistance-blocker-with-uk-firm-125022500532_1.html">https://www.business-standard.com/companies/news/venus-remedies-to-co-develop-antibiotic-resistance-blocker-with-uk-firm-125022500532_1.html</a>

## Business Standard

### Venus Remedies to co-develop antibiotic resistance blocker with UK firm

*Clinical trials to start next year, and drug can be in market by 2031-32*



| Image: LinkedIn

Date: 25 Feb 2025	Portal: Business Standard (Hindi)
Supplement – Digital	Link: <a href="https://hindi.business-standard.com/companies/venus-remedies-will-prepare-the-companys-share-after-new-research-id-416906">https://hindi.business-standard.com/companies/venus-remedies-will-prepare-the-companys-share-after-new-research-id-416906</a>

## बिज़नेस स्टैंडर्ड

### एंटीबायोटिक प्रतिरोध का तोड़ तैयार करेगी Venus Remedies, नई रिसर्च की खबर के बाद चढ़ा कंपनी का शेयर

नई दवा विकसित करने की खबर से वीनस रेमेडीज का शेयर चढ़ गया। बंबई स्टॉक एक्सचेंज पर आज यह शेयर 1.34 फीसदी चढ़कर 310.55 रुपये पर बंद हुआ।



सोहिनी दास

Last Updated- February 25, 2025 | 10:59 PM IST



Date: 26 Feb 2025	Portal: The Tribune
Supplement – Digital	Link: <a href="https://www.tribuneindia.com/news/business/india-eu-to-renew-fta-negotiations/">https://www.tribuneindia.com/news/business/india-eu-to-renew-fta-negotiations/</a>

# The Tribune

## India, EU to renew FTA negotiations

*India and the European Union will this week take stock of their negotiations for an ambitious free trade deal and broadly firm up a new strategic agenda. Venus Remedies inks pact with UK firm New Delhi: Venus Remedies said it...*



PTI  
Updated At: 09:48 AM Feb 26, 2025 IST



Date: 25 Feb 2025	Portal: Outlook Business
Supplement – Digital	Link: <a href="https://www.outlookbusiness.com/corporate/venus-remedies-inks-licensing-pact-with-uk-entity-to-develop-met-x-in-india">https://www.outlookbusiness.com/corporate/venus-remedies-inks-licensing-pact-with-uk-entity-to-develop-met-x-in-india</a>

## OUTLOOK BUSINESS


# Venus Remedies Inks Licensing Pact with UK Entity to Develop MET-X in India

*The company has entered into an exclusive licence agreement with Infex for the clinical development of MET-X.*



PTI

Updated on: 25 February 2025 1:13 pm



Venus Remedies Inks Licensing Pact with UK Entity to Develop MET-X in India

Date: 25 Feb 2025	Portal: The Week
Supplement – Digital	Link: <a href="https://www.theweek.in/wire-updates/business/2025/02/25/dcm16-biz-venus-remedies-met-x.html">https://www.theweek.in/wire-updates/business/2025/02/25/dcm16-biz-venus-remedies-met-x.html</a>

**THEWEEK**

## Venus Remedies inks licensing pact with UK entity to develop MET-X in India

*PTI* | Updated: February 25, 2025 12:30 IST

**THEWEEK**  
**PTI**  
**NEWS UPDATE**

Date: 25 Feb 2025	Portal: Express Pharma
Supplement – Digital	Link: <a href="https://www.expresspharma.in/venus-remedies-partners-with-infex-therapeutics-for-clinical-development-of-met-x-in-india/">https://www.expresspharma.in/venus-remedies-partners-with-infex-therapeutics-for-clinical-development-of-met-x-in-india/</a>



## Venus Remedies partners with Infex Therapeutics for clinical development of MET-X in India

On an exclusive licensing agreement, Venus Remedies will lead clinical trials and commercialisation of MET-X to combat antimicrobial resistance in India

By EP News Bureau — On Feb 25, 2025

LATEST UPDATES



Date: 25 Feb 2025	Portal: Biospectrum India
Supplement – Digital	Link: <a href="https://www.biospectrumindia.com/news/16/25729/venus-remedies-partners-with-uk-based-infex-the-rapeutics-to-develop-anti-bacterial-met-x-in-india.html">https://www.biospectrumindia.com/news/16/25729/venus-remedies-partners-with-uk-based-infex-the-rapeutics-to-develop-anti-bacterial-met-x-in-india.html</a>



## Venus Remedies partners with UK-based Infex Therapeutics to develop anti-bacterial MET-X in India

February 25, 2025 | Tuesday | News



**MET-X is a novel metallo-beta-lactamase inhibitor that has shown best-in-class performance in preclinical studies**



Date: 27 Feb 2025	Portal: Medgate Today
Supplement – Digital	Link: <a href="https://medgatetoday.com/venus-remedies-secures-exclusive-in-licensing-rights-from-infex-therapeutics-to-develop-and-commercialize-met-x-in-india/">https://medgatetoday.com/venus-remedies-secures-exclusive-in-licensing-rights-from-infex-therapeutics-to-develop-and-commercialize-met-x-in-india/</a>



## Venus Remedies Secures Exclusive In-Licensing Rights from Infex Therapeutics to Develop and Commercialize MET-X in India

MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies and could be game-changing for patients suffering from Gram-negative, MBL-resistant infections. Meropenem resistance in India is as high as 62-87%, with...

FEBRUARY 27, 2025 6:08 am 0 19 124 Views SHARE



- MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies and could be game-changing for patients suffering from Gram-negative, MBL-resistant infections
- Meropenem resistance in India is as high as 62-87%, with up to 50% linked to MBL prevalence, according to ICMR report
- India faces a significant burden of MBL-producing pathogens in hospital settings, and no approved MBL inhibitors currently exist in the country

Venus Remedies Ltd. (NSE: VENUSREM, BSE: 526953), a leading Indian pharmaceutical company renowned for its longstanding expertise in combatting antimicrobial resistance (AMR), today announced that it has entered into an exclusive license agreement with Infex Therapeutics, a UK-based anti-infectives specialist for the clinical development of MET-X. This agreement authorizes Venus Remedies to spearhead the clinical development, registration, and commercialization of MET-X, an innovative metallo-beta-lactamase (MBL) inhibitor. The initial development phase will focus on integrating MET-X with meropenem to tackle drug-resistant Gram-negative bacteria, with Venus Remedies holding exclusive marketing rights within India.

In India, meropenem resistance is reported to be as high as 62-87% in WHO critical priority pathogens like *K. pneumoniae* and *A. baumannii* as per the ICMR's Antimicrobial Resistance Research and Surveillance Network-Annual report 2023, with as high as 50% being directly attributable to MBL prevalence.

Under the terms of the agreement, Venus Remedies will commence with a Phase I trial involving healthy volunteers in India, evaluating MET-X in combination with meropenem. Following successful Phase I outcomes, the focus will shift to Phase II/III trials targeting drug-resistant Complicated Urinary Tract Infections (cUTIs), prevalent in hospital settings. This strategic move is aligned with Venus Remedies' extensive experience in antibiotic R&D and critical care, enhancing its leadership in the Indian critical care landscape. The

Date: 25 Feb 2025	Portal: Pharmabiz
Supplement – Digital	Link: <a href="https://www.pharmabiz.com/NewsDetails.aspx?aid=175496&amp;sid=2">https://www.pharmabiz.com/NewsDetails.aspx?aid=175496&amp;sid=2</a>

## PHARMABIZ.com

### Venus Remedies enters exclusive licensing agreement with Infex Therapeutics to develop and commercialize MET-X in India

*Our Bureau, Bengaluru*

*Tuesday, February 25, 2025, 14:45 Hrs [IST]*

Venus Remedies has entered into an exclusive license agreement with Infex Therapeutics, a UK-based anti-infectives specialist, for the clinical development of MET-X. This agreement authorizes Venus Remedies to spearhead the clinical development, registration, and commercialization of MET-X, an innovative metallo-beta-lactamase (MBL) inhibitor. The initial development phase will focus on integrating MET-X with meropenem to tackle drug-resistant gram-negative bacteria, with Venus Remedies holding exclusive marketing rights within India.

In India, meropenem resistance is reported to be as high as 62-87% in WHO critical priority pathogens like *K. pneumoniae* and *A. baumannii* as per the ICMR's Antimicrobial Resistance Research and Surveillance Network-Annual report 2023, with as high as 50% being directly attributable to MBL prevalence.

Under the terms of the agreement, Venus Remedies will commence with a phase I trial involving healthy volunteers in India, evaluating MET-X in combination with meropenem. Following successful phase I outcomes, the focus will shift to phase II/III trials targeting drug-resistant complicated urinary tract infections (cUTIs), prevalent in hospital settings.

All trials conducted in India will adhere to international standards, compliant with regulations from the FDA, EMA, and MHRA, which will also support further development and global commercialization efforts for MET-X. The agreement grants both Infex Therapeutics and Venus Remedies the option to expand their collaboration to include other MET-X/beta-lactam combinations under mutually agreed terms.

MET-X is Infex Therapeutics' broad spectrum MBL-inhibitor, targeting gram-negative bacteria. These pathogens produce MBL enzymes to deactivate beta-lactam antibiotics, such as meropenem, and evade antibiotic clearance of disease. MET-X blocks MBL resistance, restoring antibiotic activity. The drug is being developed to be one of the first broad-spectrum MBL inhibitors to address a wide range of bacterial species and MBL-resistant strains, such as *E.coli* and *K.pneumoniae*. The treatment has shown best-in-class performance in animal studies to date. The development of new agents to overcome MBL antibiotic resistance in such gram-negative bacteria is a World Health Organisation critical priority.

Saransh Chaudhary, president, global critical care, Venus Remedies and CEO, Venus Medicine Research Centre, said: "This early-stage introduction of MET-X into the Indian market leverages our decades-long dedication to AMR-focused R&D and our prominent role in critical care and antibiotic therapies. This partnership is perfectly poised to enhance our antibiotic arsenal with meropenem and explore further beta-lactam combinations, ensuring high-quality research and a significant market presence."

Date: 25 Feb 2025	Portal: Medicircle
Supplement – Digital	Link: <a href="https://medicircle.in/venus-remedies-secures-exclusive-inlicensing-rights-from-infex-therapeutics-to-develop-and-commercialize-metx-in-india">https://medicircle.in/venus-remedies-secures-exclusive-inlicensing-rights-from-infex-therapeutics-to-develop-and-commercialize-metx-in-india</a>



## Venus Remedies Secures Exclusive In-Licensing Rights from Infex Therapeutics to Develop and Commercialize MET-X in India

MediCircle / Press Release / February 25, 2025



• Venus Remedies Ltd

“ MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies and could be game-changing for patients suffering from Gram-negative, MBL-resistant infections ”



- Meropenem resistance in India is as high as 62-87%, with up to 50% linked to MBL prevalence, according to ICMR report
- India faces a significant burden of MBL-producing pathogens in hospital settings, and no approved MBL inhibitors currently exist in the country

Date: 27 Feb 2025	Portal: Indian Pharma Post
Supplement – Digital	Link: <a href="https://www.indianpharmapost.com/news/venus-remedies-secures-in-licensing-rights-from-infex-therapeutics-to-develop-and-commercialize-met-x-in-india-16834">https://www.indianpharmapost.com/news/venus-remedies-secures-in-licensing-rights-from-infex-therapeutics-to-develop-and-commercialize-met-x-in-india-16834</a>



## Venus Remedies secures in-licensing rights from Infex Therapeutics to develop and commercialize MET-X in India

*MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies*

By IPP Bureau | February 27, 2025



Venus Remedies Ltd., a leading Indian pharmaceutical company renowned for its longstanding expertise in combatting antimicrobial resistance (AMR), has entered into an exclusive license agreement with Infex Therapeutics, a UK-based anti-infectives specialist for the clinical development of MET-X.

This agreement authorizes Venus Remedies to spearhead the clinical development, registration, and commercialization of MET-X, an innovative metallo-beta-lactamase (MBL) inhibitor. The initial development phase will focus on integrating MET-X with meropenem to tackle drug-resistant Gram-negative bacteria, with Venus Remedies holding exclusive marketing rights within India.

In India, meropenem resistance is reported to be as high as 62-87% in WHO critical priority pathogens like *K. pneumoniae* and *A. baumannii* as per the ICMR's

Antimicrobial Resistance Research and Surveillance Network-Annual report 2023, with as high as 50% being directly attributable to MBL prevalence.

Under the terms of the agreement, Venus Remedies will commence with a Phase I trial involving healthy volunteers in India, evaluating MET-X in combination with meropenem. Following successful Phase I outcomes, the focus will shift to Phase II/III trials targeting drug-resistant Complicated Urinary Tract Infections (cUTIs), prevalent in hospital settings.

This strategic move is aligned with Venus Remedies' extensive experience in antibiotic R&D and critical care, enhancing its leadership in the Indian critical care landscape. The company's formidable position in meropenem marketing and manufacturing will facilitate the integration of MET-X into existing and prospective antibiotic strategies.

Date: 27 Feb 2025	Portal: India Med Today
Supplement – Digital	Link: <a href="https://indiamedtoday.com/venus-remedies-to-develop-and-commercialise-met-x-in-india/">https://indiamedtoday.com/venus-remedies-to-develop-and-commercialise-met-x-in-india/</a>



Venus Remedies has entered into an exclusive license agreement with Infex Therapeutics, a UK-based anti-infectives specialist for the clinical development of MET-X. This agreement authorises Venus Remedies to spearhead the clinical development, registration, and commercialisation of MET-X, an innovative metallo-beta-lactamase (MBL) inhibitor. The initial development phase will focus on integrating MET-X with meropenem to tackle drug-resistant Gram-negative bacteria, with Venus Remedies holding exclusive marketing rights within India.

Under the terms of the agreement, Venus Remedies will commence with a Phase I trial involving healthy volunteers in India, evaluating MET-X in combination with meropenem. Following successful Phase I outcomes, the focus will shift to Phase II/III trials targeting drug-resistant Complicated Urinary Tract Infections (cUTIs), prevalent in hospital settings.

All trials conducted in India will adhere to international standards and compliant with regulations from the FDA, EMA, and MHRA, which will also support further development and global commercialisation efforts for MET-X. The agreement grants both Infex Therapeutics and Venus Remedies the option to expand their collaboration to include other MET-X/beta-lactam combinations under mutually agreed terms.

Saransh Chaudhary, President, Global Critical Care, Venus Remedies and CEO, Venus Medicine Research Centre, said, "This early-stage introduction of MET-X into the Indian market leverages our decades-long dedication to AMR-focused R&D and our prominent role in critical care and antibiotic therapies. This partnership is perfectly poised to enhance our antibiotic arsenal with meropenem and explore further beta-lactam combinations, ensuring high-quality research and a significant market presence."

Pawan Chaudhary, CMD, Venus Remedies, "The in-licensing of MET-X is a major step forward in providing breakthrough solutions for drug-resistant infections, a serious threat to India's healthcare ecosystem. We aim to develop an effective solution against MBL-producing pathogens, fulfilling a critical healthcare need and continuing our commitment to transformative therapies and sustained innovation in critical care."

Dr Peter Jackson, CEO, Infex Therapeutics, said, "I am delighted about this agreement with Venus Remedies, which will facilitate the comprehensive clinical development of our MET-X programme in India. By leveraging Venus Remedies' robust expertise in critical care antibiotics, we can accelerate MET-X as our second clinical-stage drug program. Crucially, the international standards of these trials will also support future regulatory filings in the UK, the US, Europe, and other global markets. MET-X has shown best-in-class performance in preclinical studies and could be game-changing for patients suffering from Gram-negative, MBL-resistant infections."

Date: 27 Feb 2025	Portal: The Indian Practitioner
Supplement – Digital	Link: <a href="https://theindianpractitioner.com/venus-remedies-and-infex-therapeutics-unite-to-develop-met-x/">https://theindianpractitioner.com/venus-remedies-and-infex-therapeutics-unite-to-develop-met-x/</a>



# Venus Remedies and Infex Therapeutics Partners to Develop MET-X

By **The Indian Practitioner** - February 27, 2025



## Exclusive License Agreement for MET-X Development

Venus Remedies Ltd., a leading pharmaceutical company specializing in antimicrobial resistance (AMR), has signed an exclusive license agreement with UK-based Infex Therapeutics. Under this agreement, Venus Remedies will lead the clinical development, registration, and commercialization of MET-X, an innovative metallo-beta-lactamase (MBL) inhibitor. Initially, the company will integrate MET-X with meropenem to combat drug-resistant Gram-negative bacteria, holding exclusive marketing rights in India.

### Addressing India's Growing Antimicrobial Resistance

Meropenem resistance in India is alarmingly high, ranging from 62-87% in critical priority pathogens such as *Klebsiella pneumoniae* and *Acinetobacter baumannii*, according to the ICMR's Antimicrobial Resistance Research and Surveillance Network Annual Report 2023. With MBL prevalence directly contributing to nearly 50% of these cases, the need for an effective inhibitor is urgent.

Date: 26 Feb 2025	Portal: Clival
Supplement – Digital	Link: <a href="https://clival.com/news/venus-remedies-partners-with-infex-for-met-x-development-in-india">https://clival.com/news/venus-remedies-partners-with-infex-for-met-x-development-in-india</a>



## Venus Remedies Partners with Infex for MET-X Development in India

By, Admin

26 February 2025



Venus Remedies has entered into an exclusive license agreement with Infex Therapeutics, a UK-based anti-infectives specialist, for the clinical development of MET-X. This agreement authorizes Venus Remedies to spearhead the clinical development, registration, and commercialization of MET-X, an innovative metallo-beta-lactamase (MBL) inhibitor. The initial development phase will focus on integrating MET-X with meropenem to tackle drug-resistant gram-negative bacteria, with Venus Remedies holding exclusive marketing rights within India.

In India, meropenem resistance is reported to be as high as 62-87% in WHO critical priority pathogens like *K. pneumoniae* and *A. baumannii* as per the ICMR's Antimicrobial Resistance Research and Surveillance Network-Annual report 2023, with as high as 50% being directly attributable to MBL prevalence.

Under the terms of the agreement, Venus Remedies will commence with a phase I trial involving healthy volunteers in India, evaluating MET-X in combination with meropenem. Following successful phase I outcomes, the focus will shift to phase II/III trials targeting drug-resistant complicated urinary tract infections (cUTIs), prevalent in hospital settings.

Date: 25 Feb 2025	Portal: Devdiscourse
Supplement – Digital	Link: <a href="https://www.devdiscourse.com/article/health/3276626-venus-remedies-partners-with-infex-therapeutics-for-innovative-inhibitor">https://www.devdiscourse.com/article/health/3276626-venus-remedies-partners-with-infex-therapeutics-for-innovative-inhibitor</a>



## Venus Remedies Partners with Infex Therapeutics for Innovative Inhibitor

Venus Remedies has partnered with UK's Infex Therapeutics to develop MET-X, a metallo-beta-lactamase inhibitor aimed at combating drug-resistant gram-negative bacteria. The partnership focuses on clinical trials in India, targeting meropenem-resistant infections, with Venus leading development, registration, and commercialization efforts domestically.

Devdiscourse News Desk | New Delhi | Updated: 25-02-2025 12:21 IST | Created: 25-02-2025 12:21 IST



Date: 25 Feb 2025	Portal: Daily Excelsior
Supplement – Digital	Link: <a href="https://www.dailyexcelsior.com/venus-remedies-in-ks-licensing-pact-with-uk-entity-to-develop-met-x-in-india/">https://www.dailyexcelsior.com/venus-remedies-in-ks-licensing-pact-with-uk-entity-to-develop-met-x-in-india/</a>

DAILYEXCELSIOR.COM

## Venus Remedies inks licensing pact with UK entity to develop MET-X in India

By **Daily Excelsior** - February 25, 2025



Date: 25 Feb 2025	Portal: SME Street
Supplement – Digital	Link: <a href="https://smestreet.in/sectors/venus-remedies-partners-with-infex-for-met-x-drug-development-8755205">https://smestreet.in/sectors/venus-remedies-partners-with-infex-for-met-x-drug-development-8755205</a>



## Venus Remedies Partners with Infex for MET-X Drug Development

Under the terms of the agreement, Venus Remedies will commence with a Phase I trial involving healthy volunteers in India, evaluating MET-X in combination with meropenem.

 SMEStreet Edit Desk  
25 Feb 2025 15:04 IST



 Follow Us



Mr. Saransh Chaudhary, President, Global Critical Care, Venus Remedies Ltd

Date: 25 Feb 2025	Portal: The Bengaluru Live
Supplement – Digital	Link: <a href="https://thebengalurulive.com/venus-remedies-partners-with-infex-therapeutics-for-innovative-inhibitor/">https://thebengalurulive.com/venus-remedies-partners-with-infex-therapeutics-for-innovative-inhibitor/</a>



## Venus Remedies Partners with Infex Therapeutics for Innovative Inhibitor

By Atul Chaturvedi - February 25, 2025 12:38 PM 5 0



Venus Remedies announced a strategic partnership with UK-based Infex Therapeutics on Tuesday to develop MET-X, a groundbreaking metallo-beta-lactamase inhibitor targeting drug-resistant gram-negative bacteria.

Date: 25 Feb 2025	Portal: Business Up Turn
Supplement – Digital	Link: <a href="https://www.businessupturn.com/business/corporates/venus-remedies-secures-exclusive-rights-for-met-x-clinical-development-in-india/">https://www.businessupturn.com/business/corporates/venus-remedies-secures-exclusive-rights-for-met-x-clinical-development-in-india/</a>



## Venus Remedies secures exclusive rights for MET-X clinical development in India

 By Aman Shukla — Published on February 25, 2025, 10:16 IST



Date: 25 Feb 2025	Portal: Business News This Week
Supplement – Digital	Link: <a href="https://businessnewsthisweek.com/news/venus-remedies-secures-exclusive-in-licensing-rights-for-met-x-from-infex-therapeutics-in-india/">https://businessnewsthisweek.com/news/venus-remedies-secures-exclusive-in-licensing-rights-for-met-x-from-infex-therapeutics-in-india/</a>

## Business News This Week

# Venus Remedies Secures Exclusive In-Licensing Rights for MET-X from Infex Therapeutics in India

🕒 February 25, 2025 👤 Biswaranjan Jena 📄 news 💬 0



**Mumbai, February 25, 2025: Venus Remedies Ltd.** a leading Indian pharmaceutical company renowned for its longstanding expertise in combatting **antimicrobial resistance (AMR)**, today announced that it has entered into an exclusive license agreement with **Infex Therapeutics**, a UK-based anti-infectives specialist for the clinical development of **MET-X**. This agreement authorizes Venus Remedies to spearhead the clinical development, registration, and commercialization of **MET-X**, an innovative **metallo-beta-lactamase (MBL)** inhibitor. The initial development phase will focus on integrating **MET-X** with meropenem to tackle drug-resistant Gram-negative bacteria, with Venus Remedies holding exclusive marketing rights within India.

**In India, meropenem resistance is reported to be as high as 62-87% in WHO critical priority pathogens like K. pneumoniae and A. baumannii** as per the ICMR's Antimicrobial Resistance Research and Surveillance Network-Annual report 2023, with as high as 50% being directly attributable to MBL prevalence.

Date: 25 Feb 2025	Portal: Business Micro
Supplement – Digital	Link: <a href="https://businessmicro.in/news/venus-remedies-partners-with-infex-therapeutics-to-develop-and-commercialize-met-x-in-india/">https://businessmicro.in/news/venus-remedies-partners-with-infex-therapeutics-to-develop-and-commercialize-met-x-in-india/</a>



## Venus Remedies Partners with Infex Therapeutics to Develop and Commercialize MET-X in India

NEWS



**Mumbai, February 25, 2025:** Venus Remedies Ltd. a leading Indian pharmaceutical company renowned for its longstanding expertise in combatting **antimicrobial resistance (AMR)**, today announced that it has entered into an exclusive license agreement with **Infex Therapeutics**, a UK-based anti-infectives specialist for the clinical development of **MET-X**. This agreement authorizes Venus Remedies to spearhead the clinical development, registration, and commercialization of **MET-X**, an innovative **metallo-beta-lactamase (MBL)** inhibitor. The initial development phase will focus on integrating **MET-X** with meropenem to tackle drug-resistant Gram-negative bacteria, with Venus Remedies holding exclusive marketing rights within India.

**In India, meropenem resistance is reported to be as high as 62-87% in WHO critical priority pathogens like K. pneumoniae and A. baumannii** as per the ICMR's Antimicrobial Resistance Research and Surveillance Network-Annual report 2023, with as high as 50% being directly attributable to MBL prevalence.

Under the terms of the agreement, Venus Remedies will commence with a Phase I trial involving healthy volunteers in India, evaluating **MET-X** in combination with meropenem. Following successful Phase I outcomes, the focus will shift to Phase II/III trials targeting drug-resistant **Complicated Urinary Tract Infections (cUTIs)**, prevalent in hospital settings.

This strategic move is aligned with Venus Remedies' extensive experience in antibiotic R&D and critical care, enhancing its leadership in the Indian critical care landscape. The company's formidable position in meropenem marketing and manufacturing will facilitate the integration of **MET-X** into existing and prospective antibiotic strategies.

Date: 25 Feb 2025	Portal: News Patrolling
Supplement – Digital	Link: <a href="https://newspatrolling.com/venus-remedies-secure-exclusive-in-licensing-rights-from-infex-therapeutics-to-develop-and-commercialize-met-x-in-india/">https://newspatrolling.com/venus-remedies-secure-exclusive-in-licensing-rights-from-infex-therapeutics-to-develop-and-commercialize-met-x-in-india/</a>



## VENUS REMEDIES SECURES EXCLUSIVE IN-LICENSING RIGHTS FROM INFEX THERAPEUTICS TO DEVELOP AND COMMERCIALIZE MET-X IN INDIA

👤 Naman Bansal   🕒 February 25, 2025   📄 PR



- MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies and could be game-changing for patients suffering from Gram-negative, MBL-resistant infections
- Meropenem resistance in India is as high as 62-87%, with up to 50% linked to MBL prevalence, according to ICMR report
- India faces a significant burden of MBL-producing pathogens in hospital settings, and no approved MBL inhibitors currently exist in the country

**Bengaluru, February 25, 2025:** Venus Remedies Ltd. (NSE: VENUSREM, BSE: 526953), a leading Indian pharmaceutical company renowned for its longstanding expertise in combatting antimicrobial resistance (AMR), today announced that it has entered into an exclusive license agreement with Infex Therapeutics, a UK-based anti-infectives specialist for the clinical development of MET-X. This agreement authorizes Venus Remedies to spearhead the clinical development, registration, and commercialization of MET-X, an innovative metallo-beta-lactamase (MBL) inhibitor. The initial development phase will focus on integrating MET-X with meropenem to tackle drug-resistant Gram-negative bacteria, with Venus Remedies holding exclusive marketing rights within India.

Date: 25 Feb 2025	Portal: Indian Web2
Supplement – Digital	Link: <a href="https://www.indianweb2.com/2025/02/venus-remedies-secures-exclusive-in.html#google_vignette">https://www.indianweb2.com/2025/02/venus-remedies-secures-exclusive-in.html#google_vignette</a>



# Venus Remedies Secures Exclusive In-Licensing Rights to Develop and Commercialize MET-X in India

MET-X is [Infex Therapeutics'](#) broad spectrum MBL-inhibitor, targeting Gram-negative bacteria. These pathogens produce MBL enzymes...

By IndianWeb2 Desk on Tuesday, February 25, 2025



Date: 25 Feb 2025	Portal: Money Rediff
Supplement – Digital	Link: <a href="https://money.rediff.com/news/market/venus-remedies-partners-with-uk-firm-to-develop-met-x-for-drug-resistant-infections/22667420250225">https://money.rediff.com/news/market/venus-remedies-partners-with-uk-firm-to-develop-met-x-for-drug-resistant-infections/22667420250225</a>

**rediff** MONEYWIZ

## Venus Remedies Partners with UK Firm to Develop MET-X for Drug-Resistant Infections

By Rediff Money Desk, New Delhi Feb 25, 2025 12:18

Share on:   

Venus Remedies has partnered with Inflex Therapeutics to develop MET-X, an innovative metallo-beta-lactamase inhibitor, to tackle drug-resistant gram-negative bacteria in India. The partnership aims to address the growing concern of antibiotic resistance and provide effective treatment options for...



**Thank you**